<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228432</url>
  </required_header>
  <id_info>
    <org_study_id>19 SEIN 14</org_study_id>
    <nct_id>NCT04228432</nct_id>
  </id_info>
  <brief_title>E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.</brief_title>
  <acronym>EPOPEE</acronym>
  <official_title>E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, prospective cohort study evaluating the feasibility of an E-monitoring
      protocol in patients with breast cancer treated by adjuvant hormonotherapy .

      45 patients will be included.

      Patients will be followed during 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who do not fail the E-Monitoring protocol</measure>
    <time_frame>6 months per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of medical consultations required over 6 months</measure>
    <time_frame>6 months per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hormonotherapy adherence evaluated by the GIRERD questionnaire</measure>
    <time_frame>6 months per patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with breast cancer treated by adjuvant hormonotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dedicated and coordinated monitoring</intervention_name>
    <description>Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation
Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6.</description>
    <arm_group_label>Patients with breast cancer treated by adjuvant hormonotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient treated for hormone-dependent localized breast cancer with adjuvant HT
             (tamoxifen or anti-aromatase +/- LHRH agonist)

          2. Patient equipped with a computer or tablet computer and an internet connection at home

          3. Age &gt; 18 years old

          4. Patient affiliated to the french social security system

          5. Patient who has signed informed consent before inclusion in the study and before any
             specific procedures for the study

          6. Women of childbearing age should have effective contraception under hormonotherapy

        Exclusion Criteria:

          1. Patient with breast cancer who does not require adjuvant hormonotherapy

          2. Patient with metastatic breast cancer

          3. Any psychological, familial, geographic or social situation, according to the judgment
             of investigator, potentially preventing the provision of informed consent or
             compliance to study procedure

          4. Patient previously treated for breast cancer (infiltrating or in-situ) with adjuvant
             HT or not

          5. Patient protected by law.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DALENC</last_name>
      <phone>05 31 15 51 04</phone>
      <email>dalenc.florence@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Hormonotherapy</keyword>
  <keyword>E-monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

